Nasdaq

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am

PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.

Key Points: 
  • PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.
  • As part of Iveric Bio's lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).
  • We believe Zimura, which is a chemically synthesized RNA aptamer, is amendable to injectable sustained release formulations."
  • "This agreement underscores our commitment to invest in lifecycle initiatives for Zimura," said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio.

DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura®

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am

PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.

Key Points: 
  • PARSIPPANY, N.J. and TURKU, Finland, July 6, 2022 /PRNewswire/ -- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech's silica-based sustained release technology.
  • As part of Iveric Bio's lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).
  • We believe Zimura, which is a chemically synthesized RNA aptamer, is amendable to injectable sustained release formulations."
  • "This agreement underscores our commitment to invest in lifecycle initiatives for Zimura," said Glenn P. Sblendorio, Chief Executive Officer of Iveric Bio.

Fluence Announces India Technology Centre, Underscoring Commitment to the Region and Execution of Global Product Strategy

Retrieved on: 
Wednesday, July 6, 2022 - 6:30am

The Fluence India Technology Centre supports the execution of the companys global product strategy by growing engineering capabilities and scaling global talent and strengthens Fluences local presence in the country.

Key Points: 
  • The Fluence India Technology Centre supports the execution of the companys global product strategy by growing engineering capabilities and scaling global talent and strengthens Fluences local presence in the country.
  • The Fluence India Technology Centre marks a significant milestone for Fluence, becoming the companys first technology centre based entirely in Asia.
  • Together, the companys technology centre teams support Fluences regionally focused operational model and create a strong foundation for new product introductions and regionalized product support.
  • As the companys largest global technology team, employees at the India Technology Centre are working in the areas of enclosure, battery, and inverter engineering, software quality assurance, product management, and more.

Arab Fund for Economic and Social Development Names Northern Trust Its Asset Servicing Provider

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am

Northern Trust (Nasdaq: NTRS) today announced it has been appointed by Arab Fund for Economic and Social Development (AFESD) to provide a range of asset servicing solutions spanning global custody, financial reporting, securities finance, private equity administration, performance measurement and compliance monitoring.

Key Points: 
  • Northern Trust (Nasdaq: NTRS) today announced it has been appointed by Arab Fund for Economic and Social Development (AFESD) to provide a range of asset servicing solutions spanning global custody, financial reporting, securities finance, private equity administration, performance measurement and compliance monitoring.
  • We are pleased to be supporting AFESD and its investment activities, said Michael Slater, head of Middle East and Africa at Northern Trust.
  • Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking to corporations, institutions, affluent families and individuals.
  • Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S.

UPSTART HOLDINGS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Upstart Holdings, Inc. - UPST

Retrieved on: 
Wednesday, July 6, 2022 - 3:50am

Upstart investors should visit us at https://claimsfiler.com/cases/nasdaq-upst/ or call toll-free (844) 367-9658.

Key Points: 
  • Upstart investors should visit us at https://claimsfiler.com/cases/nasdaq-upst/ or call toll-free (844) 367-9658.
  • Upstart and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • On this news, shares of Upstart fell $43.52, or 56%, to close at $33.61 per share on May 10, 2022.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

OKTA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Okta, Inc. - OKTA

Retrieved on: 
Wednesday, July 6, 2022 - 3:50am

This action is pending in the United States District Court for the Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for the Northern District of California.
  • Okta investors should visit us at https://claimsfiler.com/cases/nasdaq-okta/ or call toll-free (844) 367-9658.
  • Okta and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

DENTSPLY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dentsply Sirona, Inc. - XRAY

Retrieved on: 
Wednesday, July 6, 2022 - 3:50am

This action is pending in the United States District Court for the Southern District of Ohio.

Key Points: 
  • This action is pending in the United States District Court for the Southern District of Ohio.
  • Dentsply investors should visit us at https://claimsfiler.com/cases/nasdaq-xray-1/ or call toll-free (844) 367-9658.
  • Dentsply and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

PEGASYSTEMS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pegasystems Inc. - PEGA

Retrieved on: 
Wednesday, July 6, 2022 - 3:50am

This action is pending in the United States District Court for the Eastern District of Virginia.

Key Points: 
  • This action is pending in the United States District Court for the Eastern District of Virginia.
  • Pegasystems investors should visit us at https://claimsfiler.com/cases/nasdaq-pega-2/ or call toll-free (844) 367-9658.
  • Pegasystems and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

HIVE Blockchain Delayed in Completion of Annual Filings Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Form 40-F

Retrieved on: 
Wednesday, July 6, 2022 - 1:00am

VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- HIVE Blockchain Technologies Ltd. (TSX.V:HIVE) (Nasdaq: HIVE) (FSE: HBFA) (the “Company” or “HIVE”) announces that it expects that its annual report on Form 40-F (the “Form 40-F”), which contains its annual audited financial statements, as well was its CEO and CFO certifications and its management discussion and analysis filing in Canada for the fiscal year ended March 31, 2022 (collectively, the “Annual Filings”) will be released after the scheduled filing date of June 29, 2022. The Company currently anticipates being able to file the Annual Filings on or before July 15, 2022. As a result of the delayed filing, the Company received a letter dated July 1, 2022 (the "Letter") from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it was not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) due to not having timely filed the 40-F. The Letter has no immediate effect on the listing or trading of HIVE’s common shares on the Nasdaq Capital Market. The Letter states that the Company is required to submit a plan to regain compliance with Rule 5250(c)(1) within 60 calendar days. If the plan is accepted by Nasdaq, then Nasdaq can grant the Company up to 180 calendar days from the due date of the Form 40-F to regain compliance.

Key Points: 
  • The Company currently anticipates being able to file the Annual Filings on or before July 15, 2022.
  • The Letter has no immediate effect on the listing or trading of HIVEs common shares on the Nasdaq Capital Market.
  • The Letter states that the Company is required to submit a plan to regain compliance with Rule 5250(c)(1) within 60 calendar days.
  • About HIVE Blockchain Technologies Ltd.
    HIVE Blockchain Technologies Ltd. went public in 2017 as the first cryptocurrency mining company with a green energy and ESG strategy.

TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX

Retrieved on: 
Wednesday, July 6, 2022 - 12:32am

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Turning Point Therapeutics, Inc. (NasdaqGS: TPTX) to Bristol Myers Squibb (NYSE: BMY).
  • Under the terms of the proposed transaction, shareholders of Turning Point will receive only $76.00 in cash for each share of Turning Point that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .